University of Minnesota
University of Minnesota

Blazar Laboratory

Research in immunobiology and transplantation


Selected Recent Publications

  • Zanin-Zhorov A, Lin J, Scher J, Kumari S, Blair D, Hippen KL, Blazar BR, Abramson SB, Lafaillie J, Dustin ML. Scaffold protein Disc-large homolog 1 is required for T cell receptor- induced activation of regulatory T cells. Proceedings National Academy of Science (USA) 109: 1625-30, 2012

  • Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, Bennett AD, Gavarret J, Vuidepot A, Zhao Y, Blazar BR, Jakobsen BK, Riley J. TCR affinity differentially affects human T regulatory and effector cell function. Blood 119:3420-30, 2012 [commentary: Greiger TL: Turning Tregs into class I suppressors. Blood 119: 3371-2, 2012]

  • Rangananthan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani S, Efebera Y, Santhanam R, Mao C, Taylor PA, Sukhinder S, He G, Sh'ana A, Nuovo J, Obad S, Broom O, Kauppinen S, Byrd JC, Caliguiri M, Perrotti D, Hadley G, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. Blood 119:4786-97, 2012.

  • Jenq RR, Ubeda C, Taur Y, Khanin R, Dudakov JA, Lui C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L,Young LF, Smith OM, Ghosh A, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MRM. Regulation of intestinal inflammation by intestinal Microbiota following allogeneic bone marrow transplantation. Journal of Experimental Medicine 209:903-11, 2012

  • Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nature Reviews Immunol 12:443-58, 2012

  • Taylor PA, Kelly RM, Bade ND, Smith MJ, Stefanski HE, Blazar BR. FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection upon its withdrawal. Biol Blood and Marrow Transplantation 18:1341-52, 2012

  • Veenstra RG, Taylor PA, Zhou Q, Panoskaltsis-Mortari A, Hirashim M, Flynn R, Liu D, Anderson AC, Strom TB, Kuchroo VJ, Blazar BR. Contrasting acute graft-versus-host disease lethality effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 19:682-90, 2012

  • Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Lui C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft vs host disease. Immunity 37:339- 50, 2012 [Preview: Diefenbach A. Interleukin-22, the guardian of the intestinal stem cell. Immunity 37:196-8, 2012]

  • Fulton LM, Carlson MJ, Coghill JM, Ott L, West ML, Panoskaltsis-Mortari A, Littman DR, Blazar BR, Serody JS. Attenuation of acute GvHD in the absence of the transcription factor RORgt. J. Immunol 189:1765-72, 2012.

  • Ding ZC, Human L, Blazar BR, Mellor AL, Munn DH, Zhou G. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 13:2229-39, 2012

  • Zuklys S, Mayer CE, Zhanybekova S, Cabellero N, Stefanski H, Nusspaumer G, Gill J, Barthlott T, Chappaz S, Nitta T, Dooley J, Takahama Y, Finke D, Liston A, Blazar BR, Pascual-Montano A, Hollander GA: miRNAs control the maintenance of thymic epithelia and their competence for T lineage commitment and thymocyte selection. J. Immunol 189:3894-904, 2012.

  • Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, Waggie KS, Peffault de Latour R, Janin A, Curtsinger JM, Dillon SR, Miller JS, Socie G, Blazar BR. 2012. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood. 119(2):619-28.
  • Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A*, Blazar BR* (co-last authors). 2012. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119(6):1570-80.
  • Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE,  Blazar BR. 2011. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Science Translational Medicine 3: 83ra41.
  • Zanin-Zhorov A, Dustin ML, Blazar BR. 2011. PKC theta and the immunological synapse: mechanisms and implications. Trends in Immunol. 32:358-63.
  • Hippen KL, Merkel SM, Schirm DK, Nelson C, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR. 2011. Generation and large-scale expansion of human inducible regulatory T cells (iTregs)  that suppress graft-versus-host disease (GVHD). Amer. J. Transplantation 11:1148-57.
  • Zhou Q, Munger ME, Veenestra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR. 2011. Co-expression of T-Cell Immunoglobulin and Mucin 3 Protein (Tim-3) and Program Death-1 (PD-1) Identifies an Exhaustion Phenotype of T cells in Mice with Dissemminated Acute Myelogenous Leukemia (AML). Blood 117:4501-10.
  • Vogtenhuber C, Bucher C, Highfill S, Jasperson LK, Goren E, Panoskaltsis-Mortari A, Taylor PA, Farrar MA, Blazar BR. 2010. Constitutively active Stat5 in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood 116:466-74.
  • Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, Brown M, Blazar BR,  Abramson SB, Lafaillie JJ, Dustin ML. 2010. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 328:372-6.
  • Holländer GA, Krenger W, Blazar BR. Emerging strategies to boost thymic function. Curr Opin Pharmacol. 443-53, 2010.
  • Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. 2010. Bone marrow myeloid-derived suppressor cells (MDSC) inhibit graft-versus-host (GVHD) disease via an arginase-1 dependent mechanism that is upregulated by IL-13.
    Blood. 116(25):5738-47.
  • Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. 2010. Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia. Blood. 116(14):2484-93.
  • Vogtenhuber C, Bucher C, Highfill S, Jasperson LK, Goren E, Panoskaltsis-Mortari A, Taylor PA, Farrar MA, Blazar BR. 2010. Constitutively active Stat5 in CD4+ T cells inhibits graft-versus-host disease (GVHD) lethality associated with increased regulatory T-cell (Treg) potency and decreased effector T cell (Teff) responses. Blood 116(3):466-74.
  • Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ, Scott HS, Gudkov AV, Hollander GA, Blazar BR. 2010. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood 115:1088-97.
  • Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A, Sivakumar P, Blazar BR. 2009. IL-21 blockcade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 114L5375-84.
  • Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Mellor AL, Munn DH, Blazar BR.2009. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 114:5062-70.
  • Zhou Q, Bucher C, Munger ME, Highfill SL, Vallera DA, Weigel BJ, Blazar BR. 2009. Combined IL2 diptheria toxin and cytotoxic T lymphocyte infusion for treating advanced acute myeloid leukemia. Blood 114:3793-802.
  • Highfill SL, Kelly RM, O’Shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A, Taylor PA, Tolar J, Blazar BR .2009. Multipotent Adult Progenitor Cells (MAPC) can suppress graft-versus-host disease via prostaglandin E-2 synthesis and only if localized to sites of allopriming. Blood.114:693-701.
  • Riley JL, June CH, Blazar BR. 2009. Human T regulatory cells as therapeutic agents: take a billion or so and call me in the morning. Immunity. [review] 30:656-65.